Published: November 17, 2009
HairDX (RxR) Genetic Test Helps Doctors Assess The Risk For Benign Prostatic Hyperplasia As Well As Finasteride Response
IRVINE, Calif. - (BUSINESS WIRE) - Pharmacogenomics research and development innovator PharmaGenoma, Inc.
and its subsidiary HairDX, LLC (www.hairdx.com)
today unveiled the next generation of its HairDX (RxR) Genetic Test for
Finasteride response. In addition to predicting Finasteride response for
the treatment of common hair loss (Androgenetic Alopecia), the test
helps doctors assess if a patient has an increased risk of developing
Benign Prostatic Hyperplasia (Enlarged Prostate).
Benign Prostatic Hyperplasia (BPH) is the age-related overgrowth of
specific prostate tissues, which often progresses to enlargement of the
prostate. An enlarged prostate can constrict the urethra, causing
various lower urinary tract symptoms.
More than half of men in their sixties and as many as 90 percent in
their seventies and eighties have some BPH symptoms, according to The
National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC).
Finasteride, used for the treatment of common hair loss, is often used
for the treatment of BPH by shrinking the size of the prostate.
"The next generation HairDX RxR test helps doctors determine if using
Finasteride may be beneficial for lowering a patient's risk of
developing an enlarged prostate due to BPH as well as potential benefits
for hair regrowth," said CEO Andy Goren.
About HairDX, LLC.
HairDX (www.hairdx.com
and Twitter:
@HairDX) is a subsidiary of PharmaGenoma, Inc., a molecular
dermatology company founded in 2007 by leading researchers and
specialists in genetics and dermatology. It is dedicated to the research
and development of new prescription based therapies for skin conditions
tailored to an individual's genetic makeup.
The company introduced HairDX, a genetic screening test for Female and
Male Pattern Baldness (Androgenetic Alopecia). The HairDX test
collection kit is listed with Japan's Pharmaceuticals
and Medical Devices Agency (PMDA) and the United States Food and Drug
Administration (FDA) as a Class I medical device.
The
HairDX Genetic Test for Hair Loss is also available as a CE Marked
product under the European In Vitro Diagnostic Directive.
In September 2009, PharmaGenoma, Inc. announced the U.S. launch of The
PsoriasisDX Genetic Test, the first commercial genetic test for
Psoriatic Arthritis.
Information on the company and its scientific/clinical advisory boards
can be found at http://www.psoriasisdx.com/About.aspx
(PsoriasisDX) and http://www.hairdx.com/About.aspx
(HairDX)
For HairDX, LLC
Jon Boroshok, 978-502-1055
jb@BiotechMarcom.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
Daily News
